Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

Unbuzzd CEO Appointment Signals Commercial Push Amidst MS Pipeline Progress

By The Northwire Desk — AI Analysis Apr 22, 2026 · 09:16 QNTM · 4.7 Quantum BioPharma Ltd.
Executive Summary
  • Event: Unbuzzd Wellness Inc., a licensee of Quantum BioPharma, appointed Richard Buzbuzian as CEO.
  • Strategy: Nationwide rollout in the United States targeting South Florida and Texas via multi-channel distribution (pharmacies, liquor stores).
  • Ownership & Royalties: Quantum retains 19.84% equity stake in Unbuzzd Wellness Inc. with a royalty agreement of 7% on sales until $250 million is reached, dropping to 3% thereafter.
  • Validation: Product backed by peer-reviewed clinical study published in World Journal of Pharmaceutical and Medical Research (2026) regarding alcohol metabolism acceleration.
  • Context: Follows previous announcements regarding the IND submission for Lucid-MS (April 1, 2026) and legal victory allowing market manipulation lawsuit to proceed (April 2, 2026).
Material Impact
  • Incremental Nature: The appointment of a CEO at a licensee is an operational milestone rather than a direct corporate catalyst for Quantum BioPharma. It confirms execution on the commercialization strategy previously hinted at in March financials and April press releases.
  • Royalty Stream Validation: While positive, this news does not guarantee immediate revenue; it validates the path to royalty generation. The market impact is muted compared to the core drug pipeline (Lucid-MS) or litigation outcomes.
  • Stock Context: The stock has declined approximately 90% from its June 2025 peak ($48.04) to current levels (~$4.70). This news does not address the fundamental valuation compression driven by clinical execution risk and litigation uncertainty.
  • Expectation Check: The market likely anticipated commercialization steps following the March 23rd publication of efficacy data. Therefore, this is priced in as a routine follow-up rather than a surprise catalyst.
QNTM · Price
Company Overview
  • Company: Quantum BioPharma Ltd. operates a dual-strategy model focusing on neurodegenerative therapeutics and consumer health products.
  • Flagship Project (Lucid-MS): Lucid-21-302 is a first-in-class, non-immunomodulatory therapy targeting demyelination in Multiple Sclerosis. Phase 1 toxicity studies completed with no safety signals; IND submitted April 1, 2026.
  • Secondary Asset (Unbuzzd): Dietary supplement for hangover relief and alcohol metabolism acceleration. Licensed to Unbuzzd Wellness Inc., providing royalty income potential without direct operational risk.
  • Pipeline Status: Lucid-MS is in Phase 2 preparation; Unbuzzd is in commercialization phase.
Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other